Full-Time

Head of R and D Platform Engineering

Confirmed live in the last 24 hours

Deadline 8/6/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$165.8k - $276.3k/yr

Senior, Expert

Toronto, ON, Canada

Category
DevOps & Infrastructure
Platform Engineering
Required Skills
Python
R
SQL
Java
AWS
Development Operations (DevOps)
Data Analysis
Snowflake
Excel/Numbers/Sheets
Requirements
  • Master’s in computer science, engineering, or a related field
  • 8-10 years of experience in platform engineering, DevOps, or software development
  • 6+ years in management and leadership roles
  • Proven track record leading successful platform projects across design, development, scaling, and maintenance
  • Understanding of R&D business and data environment strongly preferred
  • Strong communication between technical and non-technical stakeholders and collaborators
  • Demonstrated team leadership, mentorship, and management skill
  • Expertise building large-scale data platforms with supporting data lakes
  • Experience with data security, compliance, and regulatory requirements
  • Proficiency with data analytics and statistical software (incl. SQL, Python, Java, Excel, AWS, Snowflake, Informatica)
  • Expert experience with engineering tools and in programming languages such as Python, R, Java
  • Proven expertise in system integration, data streaming, data platform services, and software engineering lifecycle management
  • Deep understanding and proven track record managing large-scale platform deployments in a complex R&D environment
Responsibilities
  • Define and execute the vision and strategy for R&D platform engineering, aligning with broader R&D business objectives and data strategy needs
  • Act as liaison between technical teams and R&D business stakeholders to ensure alignment and prioritization of platform initiatives
  • Define, develop, and maintain product development roadmaps for the development of data platforms, including SIPS and SWEL
  • Lead teams of engineers and architects through the design, implementation, and optimization of SIPS and SWEL platforms to support scalable and secure R&D operations and accelerate the delivery of R&D data and AI products
  • Oversee the architecture, deployment, and maintenance of system integration and software lifecycle platforms
  • Lead and participate in technical, design, and product discussions related to the data platform; and communicate complex technical ideas to non-technical stakeholders
  • Oversee and directly manage team responsible for technical data management activities
  • Work with this team to manage data management needs from the business and provide platform level technical solutions where required
  • Collaborate with technical and non-technical teams to maximize the value of the data stack and ensure platforms meet analytical and modeling requirements
  • Ensure execution across the platform team is predictable, reliable, and sustainable, implementing best practices in engineering processes
  • Manage project timelines and priorities to ensure timely delivery of platform engineering outputs
Desired Qualifications
  • Understanding of R&D business and data environment strongly preferred

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments worldwide. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and adapt to different regulatory environments. The company's goal is to enhance health outcomes and improve the quality of life for people globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Q1 2025 profit grew by 20%, driven by new launches and Dupixent sales.
  • Tolebrutinib shows promise as a first-of-its-kind treatment for non-relapsing secondary progressive MS.
  • Sanofi's investment in Innate Pharma supports pipeline execution and strengthens strategic partnerships.

What critics are saying

  • Increased competition in multiple myeloma treatments may impact Sanofi's market share.
  • Integration challenges from recent acquisitions could delay expected synergies and benefits.
  • Regulatory scrutiny on drug pricing in the U.S. may affect Sanofi's profit margins.

What makes Sanofi unique

  • Sanofi's innovative on-body injector for Sarclisa enhances patient convenience and treatment efficiency.
  • Acquisitions of Blueprint Medicines and Vigil Neuroscience expand Sanofi's rare disease and neurology pipelines.
  • Sanofi's Dupixent is the first new targeted therapy for chronic spontaneous urticaria in a decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.

Yahoo Finance
Apr 24th, 2025
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%